Collaborative support for market access
Challenge
The product has unique mode of action in the disease area suggesting potential benefits only partially captured by clinical trials
Request
Develop a comprehensive market access strategy, including evidence generation and value messaging, to support HTA and reimbursement submissions
Response
- Developed a new model structure to capture and emphasize the product’s unique value story
- Real-world evidence (RWE) was collected and analysed to map the current treatment practice and costs
- Conducted clinical expert interviews Europewide to validate the model structure and assumptions used to capture the unique benefits
- Organised and led an advisory board of HTA and clinical experts to validate the model and assess the potential value messages
- Designed a short survey to provide local input on how the benefits would change treatment practice
- A value story was developed and incorporated into the global value dossier and other resources
